Tempest Therapeutics (TPST) Projected to Post Earnings on Monday

Tempest Therapeutics (NASDAQ:TPST) is expected to release its Q2 2026 results before the market opens on Monday, August 10th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Individuals may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Friday, August 14, 2026 at 4:00 PM ET.

Tempest Therapeutics (NASDAQ:TPST) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). On average, analysts expect Tempest Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Tempest Therapeutics Trading Up 2.9%

Tempest Therapeutics stock opened at $0.88 on Monday. The stock has a 50-day moving average price of $1.17 and a two-hundred day moving average price of $1.81. Tempest Therapeutics has a 12 month low of $0.84 and a 12 month high of $12.23. The company has a market capitalization of $14.08 million, a PE ratio of -0.15 and a beta of -1.72.

Analyst Ratings Changes

A number of equities analysts have recently commented on TPST shares. Zacks Research lowered shares of Tempest Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Wall Street Zen cut Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tempest Therapeutics in a research note on Monday, July 13th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tempest Therapeutics presently has a consensus rating of “Reduce”.

Institutional Trading of Tempest Therapeutics

A hedge fund recently bought a new position in Tempest Therapeutics stock. Dimensional Fund Advisors LP purchased a new position in shares of Tempest Therapeutics, Inc. (NASDAQ:TPST) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,444 shares of the company’s stock, valued at approximately $33,000. Dimensional Fund Advisors LP owned approximately 0.23% of Tempest Therapeutics at the end of the most recent quarter. 22.52% of the stock is owned by institutional investors and hedge funds.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.